Literature DB >> 25824791

Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.

Binhan Kagan Aktas1, Cuneyt Ozden, Suleyman Bulut, Suleyman Tagci, Guven Erbay, Cevdet Serkan Gokkaya, Mehmet Murat Baykam, Ali Memis.   

Abstract

BACKGROUND: The cancer of the prostate risk assessment (CAPRA) score has been defined to predict prostate cancer recurrence based on the pre-clinical data, then pathological data have also been incorporated. Thus, CAPRA post-surgical (CAPRA-S) score has been developed based on six criteria (prostate specific antigen (PSA) at diagnosis, pathological Gleason score, and information on surgical margin, seminal vesicle invasion, extracapsular extension and lymph node involvement) for the prediction of post-surgical recurrences. In the present study, biochemical recurrence (BCR)-free probabilities after open retropubic radical prostatectomy (RP) were evaluated by the CAPRA-S scoring system and its three-risk level model.
MATERIALS AND METHODS: CAPRA-S scores (0-12) of our 240 radical prostatectomies performed between January 2000-May 2011 were calculated. Patients were distributed into CAPRA-S score groups and also into three-risk groups as low, intermediate and high. BCR-free probabilities were assessed and compared using Kaplan-Meier analysis and Cox proportional hazards regression. Ability of CAPRA-S in BCR detection was evaluated by concordance index (c-index).
RESULTS: BCR was present in 41 of total 240 patients (17.1%) and the mean follow-up time was 51.7±33.0 months. Mean BCR-free survival time was 98.3 months (95% CI: 92.3-104.2). Of the patients in low, intermediate and high risk groups, 5.4%, 22.0% and 58.8% had BCR, respectively and the difference among the three groups was significant (P=0.0001). C-indices of CAPRA-S score and three-risk groups for detecting BCR-free probabilities in 5-yr were 0.87 and 0.81, respectively.
CONCLUSIONS: Both CAPRA-S score and its three-risk level model well predicted BCR after RP with high c-index levels in our center. Therefore, it is a clinically reliable post-operative risk stratifier and disease recurrence predictor for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25824791     DOI: 10.7314/apjcp.2015.16.6.2527

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  Does surgical delay for radical prostatectomy affect patient pathological outcome? A retrospective analysis from a Canadian cohort.

Authors:  Marc Zanaty; Mansour Alnazari; Kelsey Lawson; Mounsif Azizi; Emad Rajih; Abdullah Alenizi; Pierre-Alain Hueber; Malek Meskawi; Cedric Lebacle; Thierry Lebeau; Serge Benayoun; Pierre I Karakiewicz; Assaad El-Hakim; Kevin C Zorn
Journal:  Can Urol Assoc J       Date:  2017-08       Impact factor: 1.862

2.  Evaluating the anxiety and depression status of prostate cancer patients whose operations were postponed because of the COVID-19 pandemic.

Authors:  Yalcin Kizilkan; Samet Senel; Ali Yasin Ozercan; Melih Balci; Unsal Eroglu; Binhan Kagan Aktas; Suleyman Bulut; Cuneyt Ozden; Altug Tuncel
Journal:  Int J Clin Pract       Date:  2021-05-26       Impact factor: 3.149

Review 3.  Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?

Authors:  Zhongwei Zhao; Carsten Stephan; Sabine Weickmann; Monika Jung; Glen Kristiansen; Klaus Jung
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923

4.  External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score for Prediction of Disease Recurrence after Radical Prostatectomy.

Authors:  Taha Numan Yıkılmaz; Erdem Öztürk; Eşref Oğuz Güven; Halil Başar
Journal:  Adv Med       Date:  2016-10-19

5.  The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.

Authors:  Nigel P Murray; Socrates Aedo; Cynthia Fuentealba; Eduardo Reyes; Anibal Salazar; Eghon Guzman; Shenda Orrego
Journal:  Ecancermedicalscience       Date:  2020-06-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.